Obesity Clinical Trial
Official title:
Lifestyle Management of CKD in Obese Diabetic Patients
The purpose of this randomized clinical trial is to evaluate the efficacy of 3 different technology-supported approaches to engaging 300 individuals with diabetes and concurrent chronic kidney disease in weight loss, dietary sodium restriction, and dietary restriction of inorganic phosphates when compared to usual care. Participants will be randomized to 1 of 4 groups, Usual Care (UC), Social Cognitive Theory-based Group Counseling (SCT), Mobile self-monitoring with tailored feedback and counseling (MONITORING), or a combination of SCT plus MONITORING conditions (COMBINED). Investigators will evaluate the intervention arms primarily in terms of weight reduction, urinary sodium excretion, and serum phosphorus and, secondarily in terms of physical activity, blood pressure, fasting lipids, medication requirements, and pulse wave velocity. Measurements will occur at baseline, 6, and 12 months. The statistical modeling of the baseline, 6 mos and 12 mos outcome variables will be based on logistic generalized linear mixed models (for binary outcomes) linear mixed models (for continuous outcomes), and random effects multinomial models (for outcomes with more than 2 levels, such as changes in medication management). In separate analyses of the intervention arm only, investigators will model self-monitoring adherence and examine possible associations between self-monitoring adherence and outcomes. The mediating effect of self-efficacy on the primary outcomes will be evaluated using structural equation models.
Investigators will conduct a 2x2 factorial, randomized clinical trial. All participants will
receive usual care. Prior to randomization, participants will be stratified by recruitment
siteParticipants will be randomized to 1 of 4 groups, Usual Care (UC), Social Cognitive
Theory-based Group Counseling (SCT), Mobile self-monitoring with tailored feedback and
counseling (MONITORING), or a combination of SCT plus MONITORING conditions (COMBINED).
Investigators will evaluate the intervention arms primarily in terms of weight reduction,
urinary sodium excretion, and serum phosphorus and, secondarily in terms of physical
activity, blood pressure, fasting lipids, medication requirements, and pulse wave velocity.
Measurements will occur at baseline, 6, and 12 months. The statistical modeling of the
baseline, 6 mos and 12 mos outcome variables will be based on logistic generalized linear
mixed models (for binary outcomes) linear mixed models (for continuous outcomes), and random
effects multinomial models (for outcomes with more than 2 levels, such as changes in
medication management). In separate analyses of the intervention arm only, investigators will
model self-monitoring adherence and examine possible associations between self-monitoring
adherence and outcomes. The mediating effect of self-efficacy on the primary outcomes will be
evaluated using structural equation models
II. CHARACTERISTICS OF THE RESEARCH POPULATION
1. Number of subjects. Investigators will recruit 300 participants to the study.
Investigators will focus our study on those with diabetic CKD as this form of the disease
progresses more rapidly than other forms of CKD. Focusing on diabetic CKD also allows us to
expand logically upon Look AHEAD, and build upon our work in T2DM patients with the ENHANCE
study. Investigators will recruit participants from 3 clinical sites in New York City:
Nephrology Family Group Practice at NYU Langone Medical Center (NYULMC), the Bellevue
Hospital Diabetes Clinic, and New York Harbor VA. Preliminary data from these 3 practice
settings indicate that investigators will have access to 4,292 potentially eligible patients
from which investigators must recruit only 7.0% to enroll 300. Our prior studies suggest that
investigators will retain 80% resulting in a final sample of 240. Investigators are
projecting 64 participant measurement visits in Year 1; 248 in Year 2; 288 in Year 3; 244 in
Year 4; and 56 in Year 5.
Unless otherwise noted, measurements occur at baseline, 6, and 12 mos. Data are collected
with visits to NYU Clinical and Translational Resource Center (CTRC). Information to be
obtained from participants at each visit includes height and weight, serum and urine samples;
blood pressure; investigator administered instruments (sociodemographics, comorbid
conditions, Mini Mental Status Exam, and self-efficacy instruments), medication inventories,
and Pulse Wave Velocity. Eight blood tests will be performed: cystatin-C, lipids, phosphorus,
calcium, PTH or parathyroid hormone, vitamin D, pre-albumin and albumin. These tests are
estimated to require, in total, approximately 45 mls (of blood.
One week before their scheduled measurement visit, a 24-hour urine specimen container and
instructions for collection are mailed to the participant. Participants are contacted 2 days
prior to their appointment to remind them of their measurement visit, collect their urine,
fast, and abstain from caffeine for 12 hours prior to their appointment. Laboratory tests are
collected, spun, refrigerated, batched and sent for processing in the CLIA-certified NYU CTSI
Translational Research Laboratories by personnel blinded to group assignment. The PWV of the
brachial-ankle (baPWV) and carotid-femoral (cfPWV) will be collected by trained research
associates at the CTRC.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |